Dysregulation of iron and renal anemia treatment in patients with chronic kidney disease

Dysregulation of iron and renal anemia treatment in patients with chronic kidney disease - DIRAT-2 study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011949

Enrollment

200

Registered

2013-10-03

Start date

2013-10-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with chronic kidney disease

Interventions

Oral iron supplementation are used in priority to intravenous adminisitration as renal anemia treatment Intravenous iron administration are used as renal anemia treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic kidney disease patients who are administared erythropoiesis stimulating agents (ESA)

Exclusion criteria

Exclusion criteria: malignancy and inflammatory, gastro-intestinal, hepatic, and bone marrow diseases

Design outcomes

Primary

Measure	Time frame
Factors related to iron regulation: serum iron, transferrin saturation rate, ferritin, frataxin et al. Factors related to oxidative stress: malondialdehyde, 8OHdG, AOPP, pentosidine, GSH et al.	—

Secondary

Measure	Time frame
Factors related to inflammation: high-sensitivity CRP, interleukin-6, tumor necrosis factors-alpha, pentraxin, troponin T, et al. Factors related to nutrition: BMI, albumin, prealbumin et al.	—

Countries

Japan

Contacts

Public ContactYukiko Hasuike

Hyogo College of Medicine Dep Internal Medicine, Div Kidney and Dialysis

cherry39@hyo-med.ac.jp0798456521

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026